izpis_h1_title_alt

Applicability of RPMI 2650 and Calu-3 cell models for evaluation of nasal formulations
ID Sibinovska, Nadica (Avtor), ID Žakelj, Simon (Avtor), ID Trontelj, Jurij (Avtor), ID Kristan, Katja (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (689,95 KB)
MD5: A79BDF1F302D32E68B3BFC348C76664A
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1999-4923/14/2/369 Povezava se odpre v novem oknu

Izvleček
The RPMI 2650 and Calu-3 cell lines have been previously evaluated as models of the nasal and airway epithelial barrier, and they have demonstrated the potential to be used in drug permeation studies. However, limited data exist on the utilization of these two cell models for the assessment of nasal formulations. In our study, we tested these cell lines for the evaluation of in vitro permeation of intranasally administered drugs having a local and systemic effect from different solution- and suspension-based formulations to observe how the effects of formulations reflect on the measured in vitro drug permeability. Both models were shown to be sufficiently discriminative and able to reveal the effect of formulation compositions on drug permeability, as they demonstrated differences in the in vitro drug permeation comparable to the in vivo bioavailability. Good correlation with the available bioavailability data was also established for a limited number of drugs formulated as intranasal solutions. The investigated cell lines can be applied to the evaluation of in vitro permeation of intranasally administered drugs with a local and systemic effect from solution- and suspension-based formulations.

Jezik:Angleški jezik
Ključne besede:RPMI 2650 cell line, Calu-3 cell line, nasal drug formulations, nasal epithelium, drug permeability
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2022
Št. strani:19 str.
Številčenje:Vol. 14, iss. 2, art. 369
PID:20.500.12556/RUL-137348 Povezava se odpre v novem oknu
UDK:615
ISSN pri članku:1999-4923
DOI:10.3390/pharmaceutics14020369 Povezava se odpre v novem oknu
COBISS.SI-ID:107048707 Povezava se odpre v novem oknu
Datum objave v RUL:13.06.2022
Število ogledov:709
Število prenosov:106
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Pharmaceutics
Skrajšan naslov:Pharmaceutics
Založnik:MDPI
ISSN:1999-4923
COBISS.SI-ID:517949977 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:06.02.2022

Projekti

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Lek Pharmaceuticals, d.d., Sandoz Development Center Slovenia

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0189
Naslov:Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Public Scholarship, Development, Disability and Maintenance Fund of the Republic of Slovenia

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj